World's 2nd Richest Man Is About To Shock The World
Elon Musk changed online payment processing with Paypal. He's changing space exploration with SpaceX and the auto industry...
See what Elon is up to now.

ABEO Insider Trading (Abeona Therapeutics)

Insider Ownership Percentage: 19.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,257,806.20

Abeona Therapeutics Insider Trading History Chart

Abeona Therapeutics Share Price & Price History

$2.09
▲ +0.08 (3.98%)
As of 03/8/2021 04:59 PM ET
Days: 30 | 90 | 365
Emergency Briefing: “The Great Reset”
By May 28th, Americans could be faced with a difficult choice: Accept a "Great Reset" and risk losing the American way of life... or stand up and fight back to save what's left of the American dream. Jeff Brown, member of a D.C.-based advocacy group, explains what every American must do before May 28th to preserve his assets and thrive.
Read his full emergency briefing now

Abeona Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/18/2021Todd WiderDirectorSell321,345$2.34$751,947.30
2/8/2021Sco Capital Partners LlcDirectorSell240,000$3.01$722,400.00  
1/19/2021Sco Capital Partners LlcDirectorSell207,117$2.08$430,803.36  
1/14/2021Sco Capital Partners LlcDirectorSell31,600$2.00$63,200.00  
12/18/2020Paul Elliot MannDirectorSell17,079$1.59$27,155.61772,907  
12/2/2020Todd WiderDirectorSell33,876$1.49$50,475.24920,256  
11/23/2020Todd WiderDirectorSell17,969$1.33$23,898.77954,132  
11/2/2020Todd WiderDirectorSell33,876$1.04$35,231.04972,101  
9/10/2020Sco Capital Partners LlcDirectorSell73,411$2.08$152,694.88  
12/24/2019Stefano BuonoDirectorBuy200,000$2.50$500,000.00270,000  
4/11/2019Stefano BuonoDirectorBuy70,000$7.80$546,000.0020,980  
4/8/2019Stephen B. HowellDirectorBuy4,000$7.77$31,080.006,000  
See Full Table

SEC Filings (Institutional Ownership Changes) for Abeona Therapeutics (NASDAQ:ABEO)

36.47% of Abeona Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Abeona Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
3/8/2021Dimensional Fund Advisors LP267,414$0.42M0.0%-1.9%0.271%
2/25/2021Dimensional Fund Advisors LP267,414$0.42M0.0%-1.9%0.271%
2/24/2021Virtu Financial LLC118,030$0.19M0.0%+217.0%0.120%
2/19/2021JPMorgan Chase & Co.652,859$1.03M0.0%+49.9%0.663%
2/16/2021Squarepoint Ops LLC62,015$97K0.0%-34.9%0.063%
2/16/2021Engineers Gate Manager LP30,505$48K0.0%-62.6%0.031%
2/12/2021Credit Suisse AG17,180$27K0.0%N/A0.017%
2/11/2021Northern Trust Corp690,074$1.08M0.0%-0.6%0.700%
2/11/2021Barclays PLC81,210$0.13M0.0%-36.8%0.082%
2/10/2021Rhumbline Advisers89,874$0.14M0.0%+20.5%0.091%
2/10/2021Renaissance Technologies LLC1,322,903$2.08M0.0%+633.9%1.343%
2/10/2021QS Investors LLC215,000$0.34M0.0%N/A0.218%
2/9/2021Wells Fargo & Company MN80,942$0.13M0.0%+26.9%0.082%
2/9/2021Bank of New York Mellon Corp280,733$0.44M0.0%+7.6%0.285%
2/8/2021Russell Investments Group Ltd.216,444$0.34M0.0%+68.5%0.220%
2/5/2021BlackRock Inc.4,090,830$6.42M0.0%+5.0%4.152%
2/4/2021Los Angeles Capital Management LLC330,644$0.52M0.0%+34.0%0.336%
2/2/2021Meitav Dash Investments Ltd.92,000$0.14M0.0%+48.4%0.093%
2/1/2021Assenagon Asset Management S.A.126,344$0.20M0.0%N/A0.128%
12/11/2020Virtu Financial LLC37,232$38K0.0%N/A0.038%
11/16/2020Squarepoint Ops LLC95,295$97K0.0%+327.4%0.097%
11/16/2020Great Point Partners LLC3,892,921$3.97M0.4%-46.0%3.951%
11/13/2020Morgan Stanley96,356$99K0.0%-33.8%0.098%
11/13/2020Ardsley Advisory Partners LP25,000$26K0.0%-50.0%0.025%
11/12/2020Connor Clark & Lunn Investment Management Ltd.219,260$0.22M0.0%-23.3%0.223%
11/12/2020JPMorgan Chase & Co.435,454$0.48M0.0%+25.5%0.442%
11/10/2020State Street Corp992,946$1.01M0.0%+2.5%1.171%
10/20/2020Wedbush Securities Inc.76,700$78K0.0%N/A0.090%
9/15/2020Two Sigma Advisers LP45,400$0.13M0.0%+131.6%0.054%
8/25/2020Nuveen Asset Management LLC239,286$0.70M0.0%-50.4%0.282%
8/20/2020Charles Schwab Investment Management Inc.144,787$0.42M0.0%-3.6%0.171%
8/17/2020AQR Capital Management LLC119,162$0.35M0.0%+31.3%0.141%
8/17/2020Engineers Gate Manager LP132,218$0.39M0.0%N/A0.156%
8/14/2020Point72 Asset Management L.P.1,100,000$3.21M0.0%-34.3%1.298%
8/13/2020WS Management Lllp97,173$0.28M0.0%-14.6%0.116%
8/12/2020American International Group Inc.36,462$0.11M0.0%+12.7%0.044%
8/12/2020Goldman Sachs Group Inc.223,798$0.65M0.0%-27.6%0.267%
8/12/2020Bank of New York Mellon Corp268,930$0.78M0.0%+8.0%0.321%
8/12/2020Hudson Bay Capital Management LP475,000$1.38M0.0%+111.1%0.568%
8/12/2020Prudential Financial Inc.13,106$38K0.0%N/A0.016%
8/12/2020California Public Employees Retirement System131,969$0.39M0.0%+231.6%0.158%
8/10/2020Meitav Dash Investments Ltd.30,000$87K0.0%N/A0.036%
8/7/2020State Board of Administration of Florida Retirement System15,098$44K0.0%N/A0.018%
8/7/2020New York State Common Retirement Fund54,500$0.16M0.0%+172.5%0.065%
7/31/2020UBS Group AG27,108$79K0.0%-14.6%0.032%
7/21/2020Assenagon Asset Management S.A.74,492$0.22M0.0%-16.0%0.089%
7/20/2020SG Americas Securities LLC64,703$0.19M0.0%+438.9%0.077%
7/16/2020Rhenman & Partners Asset Management AB925,000$2.70M0.3%-2.6%1.105%
6/19/2020State Street Corp950,322$2M0.0%+55.4%1.135%
5/15/2020AQR Capital Management LLC90,742$0.19M0.0%N/A0.108%
5/15/2020Squarepoint Ops LLC24,500$51K0.0%N/A0.029%
5/15/2020Jane Street Group LLC14,444$30K0.0%N/A0.017%
5/15/2020Invesco Ltd.60,133$0.13M0.0%N/A0.072%
5/15/2020Morgan Stanley144,192$0.30M0.0%-3.0%0.172%
5/15/2020Two Sigma Advisers LP19,600$41K0.0%-16.2%0.023%
5/14/2020Wells Fargo & Company MN47,262$99K0.0%+177.5%0.056%
5/14/2020Geode Capital Management LLC886,119$1.86M0.0%+77.4%1.059%
5/14/2020Wellington Management Group LLP5,443,493$11.43M0.0%-15.9%6.504%
5/14/2020Deutsche Bank AG417,865$0.88M0.0%+1.5%0.499%
5/14/2020Alliancebernstein L.P.72,700$0.15M0.0%+94.9%0.087%
5/14/2020Nuveen Asset Management LLC482,120$1.01M0.0%+189.0%0.576%
5/13/2020Parametric Portfolio Associates LLC30,627$64K0.0%-52.9%0.037%
5/13/2020Connor Clark & Lunn Investment Management Ltd.216,292$0.45M0.0%+543.5%0.258%
5/13/2020WS Management Lllp113,799$0.24M0.0%-4.8%0.136%
5/13/2020BNP Paribas Arbitrage SA16,281$34K0.0%+104.0%0.019%
5/12/2020JPMorgan Chase & Co.256,064$0.54M0.0%+2,326.5%0.306%
5/11/2020State Street Corp950,322$2M0.0%+55.4%1.135%
5/6/2020Bank of New York Mellon Corp248,982$0.52M0.0%+24.6%0.298%
5/6/2020Rhumbline Advisers71,271$0.15M0.0%+35.7%0.085%
5/4/2020American International Group Inc.32,339$68K0.0%+54.2%0.039%
5/2/2020SG Americas Securities LLC12,007$25K0.0%-64.9%0.014%
5/1/2020BlackRock Inc.3,665,382$7.70M0.0%+47.4%4.383%
5/1/2020UBS Group AG31,750$67K0.0%-23.3%0.038%
4/29/2020Dupont Capital Management Corp70,638$0.15M0.0%N/A0.084%
4/17/2020Assenagon Asset Management S.A.88,635$0.19M0.0%N/A0.106%
4/16/2020Rhenman & Partners Asset Management AB950,000$2M0.3%-5.0%1.136%
4/9/2020Alpine Global Management LLC76,100$0.16M0.0%-84.8%0.091%
3/5/2020Nuveen Asset Management LLC166,849$0.55M0.0%-2.8%0.326%
3/2/2020Connor Clark & Lunn Investment Management Ltd.33,613$0.11M0.0%+42.9%0.066%
2/20/2020Geode Capital Management LLC499,414$1.63M0.0%+14.2%0.976%
2/19/2020Perceptive Advisors LLC1,500,000$4.91M0.1%N/A2.932%
2/17/2020Zebra Capital Management LLC15,185$50K0.0%N/A0.030%
2/14/2020Point72 Hong Kong Ltd10,262$34K0.0%N/A0.020%
2/14/2020Point72 Asset Management L.P.1,700,000$5.56M0.0%N/A3.323%
2/14/2020Perceptive Advisors LLC1,500,000$4.91M0.1%N/A2.932%
2/14/2020Cubist Systematic Strategies LLC8,078$26K0.0%N/A0.016%
2/14/2020Knoll Capital Management LP2,859,767$9.35M6.9%+21.2%5.591%
2/14/2020Schonfeld Strategic Advisors LLC1,456,700$4.76M0.1%N/A2.848%
2/14/2020Bank of America Corp DE62,102$0.20M0.0%+107.9%0.121%
2/14/2020Bank of New York Mellon Corp199,765$0.65M0.0%+36.0%0.391%
2/14/2020Marshall Wace North America L.P.494,302$1.62M0.0%N/A0.966%
2/14/2020Goldman Sachs Group Inc.278,565$0.91M0.0%+13.2%0.545%
2/14/2020UBS Group AG41,412$0.14M0.0%+62.4%0.081%
2/13/2020Oxford Asset Management LLP122,207$0.40M0.0%N/A0.239%
2/13/2020Farallon Capital Management LLC2,000,000$6.54M0.1%N/A3.910%
2/12/2020Connor Clark & Lunn Investment Management Ltd.33,613$0.11M0.0%+42.9%0.066%
2/10/2020Barclays PLC159,827$0.52M0.0%+177.0%0.312%
2/6/2020Victory Capital Management Inc.11,474$25K0.0%+144.5%0.022%
2/6/2020State Street Corp611,566$2M0.0%-3.8%1.196%
2/4/2020Victory Capital Management Inc.11,474$25K0.0%+144.5%0.022%
Data available starting January 2016

See Full Table
Abeona Therapeutics logo
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
Read More

Today's Range

Now: $2.09
$2.00
$2.13

50 Day Range

MA: $2.37
$1.91
$3.39

52 Week Range

Now: $2.09
$0.99
$3.79

Volume

98,465 shs

Average Volume

5,120,236 shs

Market Capitalization

$205.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

Who are the company insiders with the largest holdings of Abeona Therapeutics?

Abeona Therapeutics' top insider shareholders include:
  1. Todd Wider (Director)
  2. Paul Elliot Mann (Director)
  3. Stefano Buono (Director)
  4. Stephen B Howell (Director)
  5. Sco Capital Partners Llc (Director)

Who are the major institutional investors of Abeona Therapeutics?

Abeona Therapeutics' top institutional investors include:
  1. BlackRock Inc. — 4.15%
  2. Renaissance Technologies LLC — 1.34%
  3. Northern Trust Corp — 0.70%
  4. JPMorgan Chase & Co. — 0.66%
  5. Los Angeles Capital Management LLC — 0.34%
  6. Bank of New York Mellon Corp — 0.28%

Which institutional investors are selling Abeona Therapeutics stock?

In the last quarter, ABEO stock was sold by these institutional investors:
  1. Engineers Gate Manager LP
  2. Barclays PLC
  3. Squarepoint Ops LLC
  4. Dimensional Fund Advisors LP
  5. Dimensional Fund Advisors LP
  6. Northern Trust Corp
During the last year, company insiders that have sold Abeona Therapeutics company stock include:
  1. Todd Wider (Director)
  2. Paul Elliot Mann (Director)
  3. Stefano Buono (Director)

Which institutional investors are buying Abeona Therapeutics stock?

Within the previous quarter, ABEO stock was bought by institutional investors including:
  1. Renaissance Technologies LLC
  2. JPMorgan Chase & Co.
  3. QS Investors LLC
  4. BlackRock Inc.
  5. Assenagon Asset Management S.A.
  6. Russell Investments Group Ltd.
  7. Los Angeles Capital Management LLC
  8. Virtu Financial LLC
Within the previous year, these company insiders have bought Abeona Therapeutics stock:
  1. Todd Wider (Director)
  2. Paul Elliot Mann (Director)
Small Biotech Could Soar 1,000%
On December 5, 2020, a small Cambridge biotech shocked the world when they could “Find & Replace” the genes that cause the disease anemia. Investor’s Business Daily estimates the total market at $75 billion. But right now, its stock is just a tiny fraction of that size.
Here’s the next biotech we think could soar 1,000% >>>
pixel